tiotropium/olodaterol vs umeclidinium/vilanterol
Side-by-side comparison of tiotropium/olodaterol and umeclidinium/vilanterol Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Stiolto Respimat
Anoro Ellipta
Stiolto Respimat combines two medicines to help you breathe better if you have COPD. It is used long-term to manage your COPD symptoms.
Anoro Ellipta is a combination medicine used long-term to help people with COPD breathe better. It contains two medicines that open airways.
Stiolto Respimat is used to treat chronic obstructive pulmonary disease (COPD). This includes chronic bronchitis and emphysema. This medicine helps you breathe better over a long period. Stiolto Respimat is not for sudden COPD symptoms or asthma.
Anoro Ellipta is used to treat chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that makes it hard to breathe. This medicine helps to open the airways in your lungs so you can breathe easier. It is not for sudden breathing problems.
Stiolto Respimat contains two medicines that open your airways. Tiotropium helps to relax the muscles around your airways. Olodaterol is a long-acting beta-agonist (LABA) that also relaxes airway muscles.
Anoro Ellipta contains two medicines, umeclidinium and vilanterol. Umeclidinium is an anticholinergic that relaxes the muscles around your airways. Vilanterol is a LABA that also relaxes airway muscles. Together, they help to keep your airways open.
- • Common cold symptoms (nasopharyngitis)
- • Cough
- • Back pain
- • Sore throat
- • Sinus infection
- • Lower respiratory infection
- • Constipation
- • Diarrhea
No adverse event reports.
- Shortness of breath 1,352
- Medicine not working 752
- Cough 701
- Asthma 604
- Using the inhaler incorrectly 520
Using LABA medicines like Stiolto Respimat without a steroid medicine can be dangerous if you have asthma. Stiolto Respimat is not meant to treat asthma. Do not use Stiolto Respimat for sudden breathing problems. Using too much Stiolto Respimat can cause serious heart problems and may be fatal. If you have a bad reaction, like swelling or rash, stop using Stiolto Respimat and get medical help.
LABA medicines like vilanterol, when used alone for asthma, can increase the risk of serious asthma problems, including death. Anoro Ellipta is not for asthma. Do not use Anoro Ellipta if you are allergic to milk proteins or any of the ingredients in Anoro Ellipta.
Tell your doctor if you are pregnant or plan to become pregnant. Stiolto Respimat should be used during pregnancy only if the benefit outweighs the risk to the baby. It is not known if Stiolto Respimat passes into breast milk.
There is not enough information about using Anoro Ellipta during pregnancy to know if it is safe. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if Anoro Ellipta passes into breast milk.
Also Compare — Nearby Drugs
Compare tiotropium/olodaterol with
Compare umeclidinium/vilanterol with
How to Read This tiotropium/olodaterol vs umeclidinium/vilanterol Comparison
tiotropium/olodaterol is classified in the LAMA / LABA Combination drug class, while umeclidinium/vilanterol sits within the LAMA / LABA Combination class. Because both drugs share the same classification, they are often considered interchangeable in theory — but clinical outcomes rarely track that cleanly. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, tiotropium/olodaterol has 0 submissions while umeclidinium/vilanterol has 3,929. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between tiotropium/olodaterol and umeclidinium/vilanterol — always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.